MCID: LYM007
MIFTS: 65

Lymphangioleiomyomatosis malady

Categories: Genetic diseases, Rare diseases, Respiratory diseases, Immune diseases

Aliases & Classifications for Lymphangioleiomyomatosis

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Lymphangioleiomyomatosis:

Name: Lymphangioleiomyomatosis 52 11 48 25 54 70 12 50 13 68
Lam 48 25 54 70
Lymphangiomyomatosis 11 25 50
Pulmonary Lymphangioleiomyomatosis 11 68
 
Lymphangio-Myomatosis 48 27
Lymphangioleiomyomatosis, Somatic 52
Lung Lymphangioleiomyomatosis 11

Characteristics:

Orphanet epidemiological data:

54
lymphangioleiomyomatosis:
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide),1-9/1000000 (Worldwide),<1/1000000 (United States),1-9/1000000 (United States),<1/1000000 (France),1-9/1000000 (Germany),1-9/1000000 (Canada),1-9/1000000 (United Kingdom),1-9/1000000 (Switzerland),1-9/1000000 (New Zealand),1-9/1000000 (Australia),1-9/1000000 (Europe),1-9/1000000 (Netherlands); Age of onset: Adult

Classifications:



External Ids:

OMIM52 606690
Disease Ontology11 DOID:3319
NCIt45 C38153
Orphanet54 ORPHA538
SNOMED-CT62 277844007
MESH via Orphanet40 D018192
UMLS via Orphanet69 C0751674
ICD10 via Orphanet31 D48.7
MedGen37 C0751674

Summaries for Lymphangioleiomyomatosis

About this section
NIH Rare Diseases:48 Lymphangioleiomyomatosis (lim-FAN-je-o-LI-o-MI-o-ma-TO-sis), or LAM, is a rare lung disease that mostly affects women in their mid-forties. In LAM, an unusual type of cell begins to grow out of control throughout the body, including in the lungs, lymph nodes and vessels, and kidneys. Over time, these LAM cells form cysts and clusters of cells, which grow throughout the lungs and slowly block the airways. They also destroy the normal lung tissue and replace it with cysts. As a result, air cannot move freely in and out of the lungs, and the lungs cannot supply enough oxygen to the body’s other organs. More than 1 out of every 3 people with LAM also develops growths called angiomyolipomas, or AMLs, in their kidneys. People with LAM also may develop:Growths in other organs, including the liver and brain Large tumors on their lymph nodes There are two forms of LAM:Sporadic LAM, which occurs for unknown reasons LAM that occurs in people with a rare inherited disease called tuberous sclerosis complex. This is often a milder form. Last updated: 7/16/2013

MalaCards based summary: Lymphangioleiomyomatosis, also known as lam, is related to breast cancer and tsc1-related lymphangioleiomyomatosis, and has symptoms including restrictive ventilatory defect, respiratory insufficiency and pulmonary infiltrates. An important gene associated with Lymphangioleiomyomatosis is TSC2 (Tuberous Sclerosis 2), and among its related pathways are TP53 Regulates Metabolic Genes and Thyroid hormone signaling pathway. Affiliated tissues include lung, kidney and lymph node, and related mouse phenotypes are Decreased viability with paclitaxel and neoplasm.

Genetics Home Reference:25 Lymphangioleiomyomatosis (LAM) is a condition that affects the lungs, the kidneys, and the lymphatic system. The lymphatic system consists of a network of vessels that transport lymph fluid and immune cells throughout the body.

UniProtKB/Swiss-Prot:70 Lymphangioleiomyomatosis: Progressive and often fatal lung disease characterized by a diffuse proliferation of abnormal smooth muscle cells in the lungs. It affects almost exclusively young women and can occur as an isolated disorder or in association with tuberous sclerosis complex.

Wikipedia:71 Lymphangioleiomyomatosis (LAM) is a rare, progressive and systemic disease that typically results in... more...

Description from OMIM:52 606690

Related Diseases for Lymphangioleiomyomatosis

About this section

Diseases in the Lymphangioleiomyomatosis family:

Tsc1-Related Lymphangioleiomyomatosis

Diseases related to Lymphangioleiomyomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 148)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer27.5ESR1, MMP1, MMP14, MMP2, MTOR, PGR
2tsc1-related lymphangioleiomyomatosis11.8
3angiomyolipoma11.2
4tuberous sclerosis-110.8
5buschke-ollendorff syndrome10.7TSC1, TSC2
6renal clear cell carcinoma10.6TSC1, TSC2
7salpingitis isthmica nodosa10.6DES, ESR1
8vulvar angiokeratoma10.6ESR1, PGR
9spinocerebellar ataxia, autosomal recessive 210.6MTOR, TSC1
10central nervous system organ benign neoplasm10.6ESR1, PGR
11fallopian tube benign neoplasm10.6ESR1, PGR
12appendix leiomyoma10.6ESR1, PGR
13mixed cell adenoma10.6ESR1, PGR
14gelatinous ascites10.6ESR1, PGR
15deafness, autosomal dominant 8/1210.6ESR1, PGR
16perinatal intestinal perforation10.6ESR1, PGR
17trigeminal nerve disease10.6ESR1, PGR
18anterograde amnesia10.6DES, PGR
19glottis verrucous carcinoma10.6ESR1, PGR
20cerebral atrophy10.6ELN, MMP2
21bartholin's gland adenoid cystic carcinoma10.6ESR1, PGR
22bladder colonic type adenocarcinoma10.6ESR1, PGR
23mollaret meningitis10.5DES, PGR
24her2-receptor positive breast cancer10.5ESR1, PGR
25deletion 5q3510.5ELN, MMP2
26adenocarcinoma in situ10.5ESR1, PGR
27asthma susceptibility 510.5ESR1, PGR
28pathological gambling10.5MMP1, MMP2
29reading disorder10.5ELN, MMP2
30gallbladder squamous cell carcinoma10.5ESR1, PGR
31lymphocytic vasculitis10.5DES, PGR, TSC2
32bartholin's gland benign neoplasm10.5DES, ESR1
33amyloid tumor10.5ESR1, PGR
34parachordoma10.5DES, PGR, TSC2
35extracranial neuroblastoma10.5ESR1, PGR
36malignant mediastinal neurogenic neoplasm10.5ESR1, PGR
37emphysematous cholecystitis10.5MMP1, MMP2
38pilomyxoid astrocytoma10.5MTOR, TSC1, TSC2
39thoracic benign neoplasm10.5ESR1, PGR, TSC2
40cauda equina intradural extramedullary astrocytoma10.5MTOR, TSC1, TSC2
41papillary thymic adenocarcinoma10.5ESR1, PGR, TSC2
42tenosynovitis of foot and ankle10.5MTOR, TSC1, TSC2
43retroperitoneum carcinoma10.5ESR1, PGR
44dysembryoplastic neuroepithelial tumor10.4DES, PGR
45retinal dystrophies primarily involving bruch's membrane10.4ESR1, MMP2, PGR
46capillary disease10.4ESR1, PGR, TSC2
47dental caries10.4ESR1, MMP2, PGR
48keratopathy10.4MMP1, MMP2
49ovarian wilms' cancer10.4ESR1, MMP2, PGR
50classic endocrine tumor of appendix10.4ELN, MMP1

Graphical network of the top 20 diseases related to Lymphangioleiomyomatosis:



Diseases related to lymphangioleiomyomatosis

Symptoms & Phenotypes for Lymphangioleiomyomatosis

About this section


Clinical features from OMIM:

606690

Human phenotypes related to Lymphangioleiomyomatosis:

 64 54 (show all 44)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 restrictive ventilatory defect64 hallmark (90%) HP:0002091
2 respiratory insufficiency64 hallmark (90%) HP:0002093
3 pulmonary infiltrates64 54 hallmark (90%) Very frequent (99-80%) HP:0002113
4 chest pain64 54 hallmark (90%) Very frequent (99-80%) HP:0100749
5 multicystic kidney dysplasia64 typical (50%) HP:0000003
6 abnormality of female internal genitalia64 54 typical (50%) Frequent (79-30%) HP:0000008
7 hematuria64 54 typical (50%) Frequent (79-30%) HP:0000790
8 abdominal pain64 54 typical (50%) Frequent (79-30%) HP:0002027
9 emphysema64 54 typical (50%) Frequent (79-30%) HP:0002097
10 lymphadenopathy64 54 typical (50%) Frequent (79-30%) HP:0002716
11 atelectasis64 54 typical (50%) Frequent (79-30%) HP:0100750
12 ungual fibroma64 54 typical (50%) Frequent (79-30%) HP:0100804
13 polycystic kidney dysplasia64 occasional (7.5%) HP:0000113
14 hydrocephalus64 54 occasional (7.5%) Occasional (29-5%) HP:0000238
15 optic atrophy64 54 occasional (7.5%) Occasional (29-5%) HP:0000648
16 lymphedema64 54 occasional (7.5%) Occasional (29-5%) HP:0001004
17 hypermelanotic macule64 occasional (7.5%) HP:0001034
18 seizures64 54 occasional (7.5%) Occasional (29-5%) HP:0001250
19 ascites64 54 occasional (7.5%) Occasional (29-5%) HP:0001541
20 abnormality of the pericardium64 occasional (7.5%) HP:0001697
21 abnormality of the pleura64 occasional (7.5%) HP:0002103
22 hemoptysis64 54 occasional (7.5%) Occasional (29-5%) HP:0002105
23 recurrent respiratory infections64 54 occasional (7.5%) Occasional (29-5%) HP:0002205
24 gastrointestinal hemorrhage64 54 occasional (7.5%) Occasional (29-5%) HP:0002239
25 abnormality of temperature regulation64 occasional (7.5%) HP:0004370
26 retinal hamartoma64 54 occasional (7.5%) Occasional (29-5%) HP:0009594
27 shagreen patch64 54 occasional (7.5%) Occasional (29-5%) HP:0009721
28 renal neoplasm64 54 occasional (7.5%) Occasional (29-5%) HP:0009726
29 cognitive impairment64 54 occasional (7.5%) Occasional (29-5%) HP:0100543
30 pulmonary lymphangiomyomatosis64 54 Frequent (79-30%) HP:0012798
31 abnormality of skin pigmentation54 Occasional (29-5%)
32 fever54 Occasional (29-5%)
33 restrictive lung disease54 Very frequent (99-80%)
34 dyspnea54 Very frequent (99-80%)
35 pneumothorax54 Frequent (79-30%)
36 multiple renal cysts54 Occasional (29-5%)
37 renal angiomyolipoma54 Frequent (79-30%)
38 chylothorax54 Frequent (79-30%)
39 chylopericardium54 Occasional (29-5%)
40 abnormal urinary color54 Occasional (29-5%)
41 fatigue54 Occasional (29-5%)
42 macule54 Occasional (29-5%)
43 cough54 Very frequent (99-80%)
44 abnormality of the lymphatic system54 Very frequent (99-80%)

UMLS symptoms related to Lymphangioleiomyomatosis:


pain of lymph node

GenomeRNAi Phenotypes related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00293-A9.7MTOR, RPS6KB1

MGI Mouse Phenotypes related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

41 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.1ESR1, MMP1, MMP2, PGR, RPS6KB1, TSC1
2MP:00053888.0CTSK, ESR1, MMP14, MMP2, MTOR, SRF
3MP:00053807.9ESR1, MMP14, MTOR, PGR, RPS6KB1, SRF
4MP:00053907.3CTSK, ESR1, MMP14, MMP2, MTOR, MYH10
5MP:00053797.3CTSK, ESR1, MMP14, MTOR, PGR, RPS6KB1
6MP:00053697.1DES, ESR1, MMP14, MMP2, MTOR, MYH10
7MP:00028737.1ESR1, MMP14, MMP2, MTOR, MYH10, PGR
8MP:00053866.8DES, ESR1, MMP14, MTOR, MYH10, PGR
9MP:00053976.7CTSK, ESR1, MMP14, MMP2, MTOR, PGR
10MP:00053846.6CTSK, DES, ESR1, MMP14, MTOR, MYH10
11MP:00053785.9CTSK, ESR1, MMP14, MMP2, MTOR, MYH10
12MP:00107685.7DES, ESR1, MMP14, MMP2, MTOR, MYH10
13MP:00053875.7CTSK, ESR1, MMP1, MMP14, MMP2, MTOR
14MP:00053855.6DES, ESR1, MMP14, MMP2, MYH10, PGR
15MP:00053764.3CTSK, DES, ESR1, MMP1, MMP14, MMP2

Drugs & Therapeutics for Lymphangioleiomyomatosis

About this section

Drugs for Lymphangioleiomyomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 56)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxycyclineapproved, investigational, vet_approvedPhase 4237564-25-054671203
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
5-hydroxy-α-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6alpha-deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Alti-Doxycycline
Anhydrous doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline (200mg/day) or Placebo
 
Doxycycline (INN)
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
2Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
3Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 121402
4Antiprotozoal AgentsPhase 4, Phase 11986
5Antiparasitic AgentsPhase 4, Phase 12127
6AntimalarialsPhase 4, Phase 11216
7
Sirolimusapproved, investigationalPhase 3, Phase 2, Phase 1189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
8
EverolimusapprovedPhase 3, Phase 2, Phase 11896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
9
Miconazoleapproved, investigational, vet_approvedPhase 3, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
10Antifungal AgentsPhase 3, Phase 2, Phase 13615
11Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
12Antibiotics, AntitubercularPhase 3, Phase 2, Phase 16972
13
MentholapprovedPhase 223532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
14
SomatostatinapprovedPhase 222938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
15
Octreotideapproved, investigationalPhase 221383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
16
Letrozoleapproved, investigationalPhase 2382112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
17
SimvastatinapprovedPhase 1, Phase 251079902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
18
Celecoxibapproved, investigationalPhase 2435169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
19Antirheumatic AgentsPhase 2, Phase 110627
20Gastrointestinal AgentsPhase 28109
21
saracatinibPhase 2, Phase 132
Synonyms:
AZD 0530
 
AZD0530
saracatinib
22Steroid Synthesis InhibitorsPhase 21718
23EstrogensPhase 22470
24Antineoplastic Agents, HormonalPhase 25407
25Estrogen AntagonistsPhase 21315
26Hormone AntagonistsPhase 212778
27HormonesPhase 213979
28Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 212767
29Aromatase InhibitorsPhase 2807
30Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 1, Phase 21956
31Lipid Regulating AgentsPhase 1, Phase 22702
32Hypolipidemic AgentsPhase 1, Phase 22721
33AnalgesicsPhase 211287
34Anti-Inflammatory Agents, Non-SteroidalPhase 24295
35AntimetabolitesPhase 1, Phase 211774
36Cyclooxygenase InhibitorsPhase 22778
37Cyclooxygenase 2 InhibitorsPhase 2616
38Anti-Inflammatory AgentsPhase 210355
39Analgesics, Non-NarcoticPhase 26260
40Adrenergic beta-AgonistsPhase 21640
41AlbuterolPhase 2408
42Anti-Asthmatic AgentsPhase 23369
43Adrenergic beta-2 Receptor AgonistsPhase 2925
44Adrenergic AgonistsPhase 22877
45Adrenergic AgentsPhase 25140
46Anticholesteremic AgentsPhase 1, Phase 21983
47Autonomic AgentsPhase 29774
48Tocolytic AgentsPhase 2708
49Liver ExtractsPhase 23868
50Bronchodilator AgentsPhase 22856

Interventional clinical trials:

(show all 28)
idNameStatusNCT IDPhase
1Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
2Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)Unknown statusNCT00414648Phase 3
3Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
4Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMUnknown statusNCT00490789Phase 2
5Trial of Aromatase Inhibition in LymphangioleiomyomatosisCompletedNCT01353209Phase 2
6A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With LymphangioleiomyomatosisCompletedNCT01059318Phase 2
7Treatment With Octreotide in Patients With LymphangioleiomyomatosisCompletedNCT00005906Phase 2
8Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
9Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
10RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
11Nebulized or Inhaled Albuterol for LymphangioleiomyomatosisRecruitingNCT01799538Phase 2
12Safety and Efficacy of Saracatinib In Subjects With LymphangioleiomyomatosisRecruitingNCT02737202Phase 2
13Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
14COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSCRecruitingNCT02484664Phase 2
15The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)CompletedNCT02116712Phase 1
16Safety Study of Sirolimus and Hydroxychloroquine in Women With LymphangioleiomyomatosisCompletedNCT01687179Phase 1
17National Lymphangioleiomyomatosis Registry, FranceUnknown statusNCT01484236
18Pulmonary Rehabilitation in LymphangioleiomyomatosisCompletedNCT02009241
19Pulmonary Hypertension in LymphangioleiomyomatosisCompletedNCT00960895
20Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)CompletedNCT00001869
21Lymphangioleiomyomatosis (LAM) RegistryCompletedNCT00005486
22Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
23Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System DiseasesCompletedNCT00366509
24Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and AngiomyolipomaRecruitingNCT02325505
25Study of the Disease Process of LymphangioleiomyomatosisRecruitingNCT00001465
26Safety and Durability of Sirolimus for Treatment of LAMRecruitingNCT02432560
27The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation PatientsRecruitingNCT02859194
28Lymphatic Anomalies RegistryRecruitingNCT02399527

Search NIH Clinical Center for Lymphangioleiomyomatosis

Genetic Tests for Lymphangioleiomyomatosis

About this section

Genetic tests related to Lymphangioleiomyomatosis:

id Genetic test Affiliating Genes
1 Lymphangiomyomatosis27

Anatomical Context for Lymphangioleiomyomatosis

About this section

MalaCards organs/tissues related to Lymphangioleiomyomatosis:

36
Lung, Kidney, Lymph node, Smooth muscle, Liver, Brain, Endothelial

Publications for Lymphangioleiomyomatosis

About this section

Articles related to Lymphangioleiomyomatosis:

(show top 50)    (show all 611)
idTitleAuthorsYear
1
A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis. (26799509)
2016
2
Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspective. (27730199)
2016
3
Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. (26725158)
2016
4
Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. (27108015)
2016
5
Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis. (27016587)
2016
6
Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. (26997436)
2016
7
A case of lymphangioleiomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus. (27377753)
2016
8
Efficacy and Safety of Long-term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. (27513278)
2016
9
A Case of Successful Therapy by Intrapleural Injection of Fibrin Glue for Chylothorax after Lung Transplantation for Lymphangioleiomyomatosis. (27431923)
2016
10
Lung Transplantation for Lymphangioleiomyomatosis in Japan. (26771878)
2016
11
Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells. (27502989)
2016
12
Should lymphangioleiomyomatosis patients be permitted to donate blood? (27103385)
2016
13
Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation. (27011924)
2016
14
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. (27628078)
2016
15
A Total Pleural Covering for Lymphangioleiomyomatosis Prevents Pneumothorax Recurrence. (27658250)
2016
16
Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. (26917604)
2016
17
Solitary extrapulmonary lymphangioleiomyomatosis of the liver: A case report and literature review. (27588070)
2016
18
mTOR treatment in lymphangioleiomyomatosis: the role of everolimus. (26847859)
2016
19
Role of Prolactin Receptors in Lymphangioleiomyomatosis. (26765535)
2016
20
NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. (27734028)
2016
21
Pulmonary lymphangioleiomyomatosis in a 46-year-old female: A case report and review of the literature. (27284412)
2016
22
Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer. (27409646)
2016
23
Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model. (26880751)
2016
24
Lung cancer in a patient with lymphangioleiomyomatosis. (27986407)
2016
25
A Case of Sporadic Pulmonary Lymphangioleiomyomatosis. (27685825)
2016
26
Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis. (27882343)
2016
27
Incidence of Pneumothorax in Patients With Lymphangioleiomyomatosis Undergoing Pulmonary Function and Exercise Testing. (27396798)
2016
28
Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis. (27171001)
2016
29
Lymphangioleiomyomatosis. (27514586)
2016
30
Study of breast cancer incidence in patients of lymphangioleiomyomatosis. (26951504)
2016
31
Coexistence of pulmonary lymphangioleiomyomatosis and pulmonary angiomyolipoma. (27527652)
2016
32
Characteristics of Patients with Lymphangioleiomyomatosis and Pleural Effusion: A Systematic Review. (26938102)
2016
33
Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. (26968971)
2016
34
Two Kinds of Cystic Lung Lesions with Pulmonary Lymphangioleiomyomatosis in a Male. (27349306)
2016
35
Imaging Biomarkers in Lymphangioleiomyomatosis Clinical Trials. A Wolf in Sheep's Clothing? (26963351)
2016
36
EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS. (27833825)
2016
37
Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis. (27289491)
2016
38
Incidental pulmonary lymphangioleiomyomatosis in a patient with breast cancer. (27185512)
2016
39
Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. (26915883)
2016
40
Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing. (26563443)
2015
41
Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis (LAM). (26432869)
2015
42
Lymphangioleiomyomatosis (LAM)--questions. (26333214)
2015
43
Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis. (26321137)
2015
44
Treatment of lymphangioleiomyomatosis and CamA/es. (26398747)
2015
45
Antibody I+PEP13h reacts with lymphangioleiomyomatosis cells in lung nodules. (25411763)
2015
46
Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. (26386638)
2015
47
Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM). (26422572)
2015
48
Incidental Pelvic and Para-aortic Lymph Node Lymphangioleiomyomatosis Detected During Surgical Staging of Pelvic Cancer in Women Without Symptomatic Pulmonary Lymphangioleiomyomatosis or Tuberous Sclerosis Complex. (25786086)
2015
49
Lung Transplantation for Lymphangioleiomyomatosis in a Single Japanese Institute, With a Focus on Late-onset Complications. (26293084)
2015
50
Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangioleiomyomatosis. (26317276)
2015

Variations for Lymphangioleiomyomatosis

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lymphangioleiomyomatosis:

70
id Symbol AA change Variation ID SNP ID
1TSC2p.Arg611GlnVAR_005650rs28934872

Clinvar genetic disease variations for Lymphangioleiomyomatosis:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TSC2NM_000548.4(TSC2): c.5024C> T (p.Pro1675Leu)SNVPathogenicrs45483392GRCh37Chr 16, 2137898: 2137898
2TSC2NM_000548.4(TSC2): c.1513C> T (p.Arg505Ter)SNVPathogenicrs45517179GRCh37Chr 16, 2114342: 2114342
3TSC2NM_000548.4(TSC2): c.1832G> A (p.Arg611Gln)SNVPathogenicrs28934872GRCh37Chr 16, 2120572: 2120572
4TSC2NM_000548.4(TSC2): c.1096G> T (p.Glu366Ter)SNVPathogenicrs45517148GRCh37Chr 16, 2110791: 2110791
5TSC2NM_000548.4(TSC2): c.5238_5255del18 (p.His1746_Arg1751del)deletionPathogenicrs137854218GRCh37Chr 16, 2138305: 2138322
6TSC1NM_000368.4(TSC1): c.491G> A (p.Trp164Ter)SNVPathogenicrs118203387GRCh37Chr 9, 135798752: 135798752
7TSC1NM_000368.4(TSC1): c.495C> A (p.Cys165Ter)SNVPathogenicrs118203388GRCh37Chr 9, 135798748: 135798748

Expression for genes affiliated with Lymphangioleiomyomatosis

About this section
Search GEO for disease gene expression data for Lymphangioleiomyomatosis.

Pathways for genes affiliated with Lymphangioleiomyomatosis

About this section

Pathways related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

(show all 31)
idSuper pathwaysScoreTop Affiliating Genes
19.8MTOR, TSC1, TSC2
29.8ESR1, MTOR, TSC2
3
Show member pathways
9.6VEGFC, VEGFD
49.5ESR1, MTOR, TSC1, TSC2
5
Show member pathways
9.5MTOR, RPS6KB1, TSC2
69.5MTOR, RPS6KB1, TSC2
79.4ESR1, MTOR, RPS6KB1
89.4ESR1, MTOR, RPS6KB1
99.4SRF, TSC2
109.4MMP1, MMP14, MMP2
11
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
12
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
13
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
149.3MTOR, RPS6KB1, TSC1, TSC2
15
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
16
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
179.3MTOR, RPS6KB1, TSC1, TSC2
18
Show member pathways
9.3MTOR, RPS6KB1, TSC1, TSC2
199.3MMP2, VEGFC, VEGFD
20
Show member pathways
9.2MMP2, MTOR, RPS6KB1, TSC2
219.2ESR1, MMP1, MTOR, TSC1, TSC2
229.2ESR1, MMP2, MTOR, RPS6KB1
23
Show member pathways
8.9CTSK, MMP1, MMP14, MMP2
248.7MMP1, MMP2, MTOR, VEGFC, VEGFD
25
Show member pathways
8.5CTSK, ELN, MMP1, MMP14, MMP2
26
Show member pathways
8.5ESR1, MMP14, MMP2, MTOR, RPS6KB1, TSC2
278.5MTOR, RPS6KB1, SRF, TSC1, TSC2
28
Show member pathways
8.4MTOR, RPS6KB1, TSC1, TSC2, VEGFC, VEGFD
298.4MTOR, RPS6KB1, TSC1, TSC2, VEGFC, VEGFD
30
Show member pathways
8.3ESR1, RPS6KB1, TSC1, TSC2, VEGFC, VEGFD
31
Show member pathways
6.8DES, ELN, ESR1, MTOR, MYH10, SRF

GO Terms for genes affiliated with Lymphangioleiomyomatosis

About this section

Cellular components related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1TSC1-TSC2 complexGO:003359610.0TSC1, TSC2
2extracellular regionGO:00055767.7CTSK, ELN, MMP1, MMP2, PMEL, VEGFC

Biological processes related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

(show all 18)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of cell sizeGO:004579210.6MTOR, TSC1
2negative regulation of macroautophagyGO:001624210.6MTOR, TSC1
3positive regulation of myotube differentiationGO:001083110.4MMP14, MTOR
4intramembranous ossificationGO:000195710.3CTSK, MMP2
5induction of positive chemotaxisGO:005093010.2VEGFC, VEGFD
6positive regulation of mast cell chemotaxisGO:006075410.2VEGFC, VEGFD
7regulation of vascular endothelial growth factor receptor signaling pathwayGO:003094710.2VEGFC, VEGFD
8negative regulation of insulin receptor signaling pathwayGO:004662710.1RPS6KB1, TSC1, TSC2
9positive chemotaxisGO:005091810.0TSC2, VEGFC, VEGFD
10cardiac myofibril assemblyGO:00550039.9MYH10, SRF
11response to insulinGO:00328689.9MTOR, RPS6KB1, TSC1
12TOR signalingGO:00319299.7MTOR, RPS6KB1
13stress fiber assemblyGO:00431499.6ELN, SRF
14collagen catabolic processGO:00305749.5CTSK, MMP1, MMP14, MMP2
15long-term memoryGO:00076169.5MTOR, RPS6KB1, SRF
16angiogenesisGO:00015259.5MMP14, MMP2, VEGFC, VEGFD
17extracellular matrix disassemblyGO:00226179.2CTSK, ELN, MMP1, MMP14, MMP2
18response to hypoxiaGO:00016668.8MMP14, MMP2, SRF, VEGFD

Molecular functions related to Lymphangioleiomyomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1metalloendopeptidase activityGO:000422210.2MMP1, MMP14, MMP2
2vascular endothelial growth factor receptor 3 bindingGO:00431859.6VEGFC, VEGFD
3serine-type endopeptidase activityGO:00042528.8CTSK, MMP1, MMP14, MMP2
4protein bindingGO:00055155.0CTSK, DES, ELN, ESR1, MMP14, MMP2

Sources for Lymphangioleiomyomatosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet